Source transparency
A public map from every research article to its visible source trail.
This inventory lets readers, editors, educators, and developers inspect which source publishers and URLs support each of the 100 public PeptideSchool research guides. It records provenance without turning reference counts into evidence scores.
Educational content only. Not medical advice.
Published by PeptideSchool Editorial Desk · Published and reviewed August 11, 2026
Visible source coverage
Every guide keeps its trail
- Articles
- 100
- Article families
- 6
- Source references
- 257
- Unique source URLs
- 125
- Source domains
- 30
- Publishers
- 53
How it works
Every listed guide is checked against the sources readers can inspect on the page.
We keep the article title, editorial family, publication and review dates, source title, publisher, and visible link together. This gives readers a traceable research trail while leaving customer data, member content, and internal performance information out of the public record.
Included public facts
Canonical URL, title, family, dates, institutional author, source titles, publishers, URLs, domains, and the count of related public guides.
Excluded protected data
Search keywords, rankings, impressions, clicks, conversions, user data, internal performance, Premium content, protocols, dosage recommendations, and medical advice.
A listed reference proves that a source trail is visible on the article. It does not prove that every source is equally strong, that a conclusion applies to a person, or that a substance has a particular regulatory status. Study design, relevance, methods, limitations, jurisdiction, and publication date still require direct review.
Coverage by editorial family
All 100 canonical research guides are represented.
15
Research profiles
38 listed source references across this family.
18
Science topics
41 listed source references across this family.
7
Comparisons
18 listed source references across this family.
38
Research methods
100 listed source references across this family.
6
Math and units
12 listed source references across this family.
16
Glossary guides
48 listed source references across this family.
Article-to-source map
Inspect every public record before downloading.
The lists below expose every included article in visible HTML. Open an article to read its complete source notes and evidence limits, or use JSON when you need the full structured source objects.
Research profiles15 records
Retatrutide: triple-agonist design, phase 2 evidence, and open questions3 sources · clinicaltrials.gov, fda.gov, nejm.orgTirzepatide: dual-agonist biology, trial evidence, and interpretation3 sources · clinicaltrials.gov, fda.gov, nejm.orgSemaglutide: GLP-1 receptor biology, STEP evidence, and limits3 sources · accessdata.fda.gov, clinicaltrials.gov, nejm.orgMazdutide: GLP-1/glucagon dual agonism and the clinical evidence3 sources · clinicaltrials.gov, pmc.ncbi.nlm.nih.govMOTS-c: mitochondrial encoding, metabolic research, and evidence limits3 sources · fda.gov, pmc.ncbi.nlm.nih.govSS-31 (elamipretide): mitochondrial targeting, trials, and narrow regulatory context3 sources · clinicaltrials.gov, fda.gov, nature.comGHK-Cu: copper-binding biology, experimental evidence, and claim limits3 sources · medlineplus.gov, pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.govBPC-157: what preclinical research suggests and human evidence cannot yet show3 sources · fda.gov, pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.govEndogenous GLP-1 Is a Processed Product of Proglucagon2 sources · ncbi.nlm.nih.gov, uniprot.orgEndogenous GIP as a Nutrient-Responsive Peptide Hormone2 sources · ncbi.nlm.nih.gov, uniprot.orgGlucagon Is One Product of a Multi-Peptide Precursor2 sources · ncbi.nlm.nih.gov, uniprot.orgFrom Preproinsulin to Two-Chain Insulin2 sources · ncbi.nlm.nih.gov, uniprot.orgC-Peptide Connects the Insulin Chains Before Processing2 sources · ncbi.nlm.nih.gov, uniprot.orgSomatostatin-14 and Somatostatin-28 Share a Precursor2 sources · ncbi.nlm.nih.gov, uniprot.orgGhrelin Requires a Specific Acyl Modification for Canonical GHSR Signaling2 sources · ncbi.nlm.nih.gov, uniprot.org
Science topics18 records
Incretin agonists: a map of GLP-1, GIP, and glucagon research4 sources · nejm.org, pmc.ncbi.nlm.nih.govMitochondrial-derived peptides and mitochondria-targeted peptide research3 sources · cell.com, fda.gov, nature.comGrowth hormone secretagogues: classes, signals, and evidence limits3 sources · ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.govCopper-binding peptides: GHK-Cu, AHK-Cu, and the evidence map3 sources · meshb.nlm.nih.gov, pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.govHow Peptide Hormones Are Made, Released, and Detected2 sources · guidetopharmacology.org, uniprot.orgNeuropeptides as Slow, Context-Dependent Neural Signals2 sources · guidetopharmacology.org, uniprot.orgAntimicrobial Peptides Are More Than Membrane-Disrupting Molecules2 sources · pmc.ncbi.nlm.nih.govHow Cyclization Changes Peptide Structure and Function2 sources · rcsb.org, uniprot.orgThe Evidence Chain Behind Peptide Therapeutic Development2 sources · clinicaltrials.gov, fda.govWhy Peptide Delivery Is a Multibarrier Research Problem2 sources · fda.gov, pmc.ncbi.nlm.nih.govHow Peptide Half-Life Extension Strategies Change a Molecule2 sources · pmc.ncbi.nlm.nih.govHow Lipidation Changes Peptide Distribution and Persistence2 sources · pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.govPEGylated Peptides Require More Than a Molecular-Weight Label2 sources · fda.gov, pubmed.ncbi.nlm.nih.govHow Fusion Partners Change Peptide Products2 sources · fda.gov, pmc.ncbi.nlm.nih.govPeptide Binding Is Only the First Step in Receptor Signaling2 sources · guidetopharmacology.org, rcsb.orgWhy Receptor Signaling Changes During Continued Stimulation2 sources · guidetopharmacology.orgHow Peptide Immunogenicity Risk Is Assessed2 sources · fda.govHow Peptidomimetics Reproduce Selected Peptide Features2 sources · pubchem.ncbi.nlm.nih.gov, rcsb.org
Comparisons7 records
Tirzepatide vs retatrutide vs mazdutide: receptors, trials, and comparison limits3 sources · nejm.org, pmc.ncbi.nlm.nih.govSS-31 vs MOTS-c: origin, mechanism, evidence, and development status4 sources · fda.gov, nature.com, pmc.ncbi.nlm.nih.govPercent Solutions, Ratio Strength, and ppm Are Not Interchangeable2 sources · fda.gov, nist.govRelative Risk, Absolute Risk, and Odds Ratios Are Different Measures2 sources · equator-network.org, pmc.ncbi.nlm.nih.govPreclinical vs Clinical Evidence: What Each Can Support3 sources · arriveguidelines.org, clinicaltrials.gov, pmc.ncbi.nlm.nih.govMolarity vs Mass Concentration: What Each One Measures2 sources · bipm.org, nist.govOxytocin and Vasopressin Are Related but Distinct Peptide Systems2 sources · uniprot.org
Research methods38 records
A reproducible method for searching peptide literature3 sources · clinicaltrials.gov, meshb.nlm.nih.gov, pubmed.ncbi.nlm.nih.govHow to verify a PubMed citation before using it3 sources · crossref.org, medlineplus.gov, pubmed.ncbi.nlm.nih.govHow to read ClinicalTrials.gov without overclaiming3 sources · clinicaltrials.govA claim-checking checklist for peptide research3 sources · clinicaltrials.gov, fda.gov, medlineplus.govMeasurement Uncertainty, Precision, and Significant Figures2 sources · nist.govP-Values and Statistical Significance: What They Do Not Prove2 sources · doi.org, pmc.ncbi.nlm.nih.govHow to Read a Randomized Controlled Trial Step by Step3 sources · clinicaltrials.gov, pmc.ncbi.nlm.nih.govHow to Read a Systematic Review and Meta-Analysis3 sources · bmj.com, equator-network.org, training.cochrane.orgHow to Read Syringe Graduations in a Non-Clinical Research Context2 sources · fda.gov, nist.govReading Research Tables, Error Bars, and Logarithmic Axes2 sources · clinicaltrials.gov, itl.nist.govMean, Median, and Standard Deviation: Reading Study Results2 sources · clinicaltrials.gov, itl.nist.govHow to Read Confidence Intervals and Effect Sizes2 sources · pmc.ncbi.nlm.nih.govReading Research Vial Labels: Identity, Strength, and Units2 sources · fda.govClinical trial endpoints: what a study measures and why it matters3 sources · clinicaltrials.gov, fda.govPrimary, secondary, and exploratory endpoints: why hierarchy matters3 sources · clinicaltrials.gov, fda.govRandomization in clinical trials: sequence, balance, and valid comparison3 sources · fda.gov, pmc.ncbi.nlm.nih.gov, training.cochrane.orgBlinding and masking in research: who knows what, and when3 sources · fda.gov, pmc.ncbi.nlm.nih.gov, training.cochrane.orgAllocation concealment vs blinding: two protections at different times3 sources · fda.gov, pmc.ncbi.nlm.nih.gov, training.cochrane.orgIntention-to-treat vs per-protocol: two different trial questions3 sources · fda.gov, pmc.ncbi.nlm.nih.gov, training.cochrane.orgStatistical power and sample size: what a study was designed to detect3 sources · fda.gov, pmc.ncbi.nlm.nih.govMultiple comparisons: why more tests create more chances for false positives3 sources · fda.gov, grants.nih.govPreregistration, protocols, and analysis plans: separating prediction from discovery3 sources · fda.gov, grants.nih.govEligibility criteria and external validity: who a trial can inform3 sources · clinicaltrials.gov, fda.gov, pmc.ncbi.nlm.nih.govAdverse events, serious adverse events, and safety signals: terms that are not interchangeable3 sources · clinicaltrials.gov, fda.govTranslational research: how findings move between models and human questions3 sources · cancer.gov, grants.nih.gov, ncats.nih.govAssay validation: proving a method is fit for its intended purpose3 sources · fda.gov, ncbi.nlm.nih.gov, nist.govBatch-to-batch variability: when the named material is not the same experiment3 sources · fda.gov, grants.nih.govPurity, identity, and contamination: three separate analytical questions3 sources · fda.gov, nist.govReplication vs reproducibility: new evidence and repeatable analysis3 sources · grants.nih.gov, nap.nationalacademies.orgBias, confounding, and effect modification: three different explanations for a result3 sources · cdc.gov, fda.gov, training.cochrane.orgMissing data, attrition, and censoring: assumptions behind incomplete outcomes3 sources · fda.gov, nap.nationalacademies.org, training.cochrane.orgHow Peptides Degrade and How Stability Is Studied2 sources · fda.gov, hhs.govHow Solid-Phase Peptide Synthesis Builds a Sequence2 sources · nature.com, pubmed.ncbi.nlm.nih.govHow Recombinant Systems Produce Peptides and Precursors2 sources · fda.govHow Chromatography Separates Peptides and Related Impurities2 sources · fda.govNo Single Test Fully Characterizes a Peptide2 sources · fda.govWhat Mass Spectrometry Can and Cannot Prove About a Peptide2 sources · fda.gov, pubmed.ncbi.nlm.nih.govHow to Use Peptide Sequence Databases Without Losing Context2 sources · ncbi.nlm.nih.gov, uniprot.org
Math and units6 records
How SI Units and Metric Prefixes Work in Research2 sources · nist.govDilution Factors and Serial Dilutions: The Underlying Math2 sources · bipm.org, nist.govHow Solvent Addition Changes Final Concentration2 sources · fda.gov, nist.govDimensional Analysis: A Safer Way to Check Research Math2 sources · bipm.org, nist.govScientific Notation for Reading Small Research Quantities2 sources · nist.govMass, Concentration, and Volume Are Different Quantities2 sources · bipm.org, fda.gov
Glossary guides16 records
Peptide vs protein: what the terms mean and where the boundary blurs3 sources · meshb.nlm.nih.gov, ncbi.nlm.nih.govPeptide aliases and nomenclature: how to verify that two names mean the same molecule4 sources · clinicaltrials.gov, meshb.nlm.nih.gov, pubchem.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.govConcentration, Dose, Amount, and Volume: A Research Glossary3 sources · bipm.org, clinicaltrials.gov, fda.govClinical trial phases explained: development questions, not quality grades3 sources · clinicaltrials.gov, fda.govPharmacokinetics basics: absorption, distribution, metabolism, and elimination3 sources · fda.gov, ncbi.nlm.nih.govBiological half-life and steady state: what concentration-time summaries assume3 sources · ncbi.nlm.nih.govBioavailability and route comparisons: rate, extent, and formulation context3 sources · fda.gov, ncbi.nlm.nih.govReceptor agonists, antagonists, and partial agonists: a functional glossary3 sources · ncbi.nlm.nih.govSelectivity vs specificity: relative preference, assay discrimination, and context3 sources · fda.gov, ncbi.nlm.nih.govPotency vs efficacy: position and maximum on a concentration-response curve3 sources · ncbi.nlm.nih.govAffinity, Kd, IC50, and EC50: binding constants and operational assay values3 sources · ncbi.nlm.nih.govIn vitro, in vivo, and ex vivo: three model contexts with different limits3 sources · cancer.govReference standards and calibration: connecting an instrument response to a known value3 sources · fda.gov, nist.govChromatography and HPLC basics: separation, retention, detection, and limits3 sources · fda.gov, nist.govMass spectrometry basics: ions, mass-to-charge, fragmentation, and identification3 sources · fda.gov, nist.govA Peptide Name Is Not a Complete Molecular Identity2 sources · pubmed.ncbi.nlm.nih.gov, uniprot.org
Technical files for researchers and developers
Most visitors do not need these files. They support structured review and citation of the source map.
JSON inventoryAll article and source recordsCSV inventoryOne auditable row per articleJSON SchemaMachine-readable field contractSHA-256 checksumsIntegrity receipt for every fileLicenseCC BY 4.0 terms and attribution
The manifest verifies the JSON, CSV, JSON Schema, and license bytes with SHA-256. Dataset structure and original PeptideSchool wording are CC BY 4.0; third-party source titles, publications, trademarks, and linked materials remain with their respective owners.
Reading path